A detailed history of Colony Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Colony Group LLC holds 80,387 shares of HALO stock, worth $3.82 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
80,387
Previous 80,382 0.01%
Holding current value
$3.82 Million
Previous $2.9 Million 5.93%
% of portfolio
0.05%
Previous 0.04%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $182 - $220
5 Added 0.01%
80,387 $3.07 Million
Q2 2023

Aug 15, 2023

SELL
$30.28 - $38.74 $3,149 - $4,028
-104 Reduced 0.13%
80,382 $2.9 Million
Q1 2023

May 16, 2023

SELL
$32.86 - $55.7 $35,883 - $60,824
-1,092 Reduced 1.34%
80,486 $3.07 Million
Q4 2022

Feb 14, 2023

BUY
$40.06 - $59.44 $62,293 - $92,429
1,555 Added 1.94%
81,578 $4.64 Million
Q3 2022

Nov 15, 2022

SELL
$38.53 - $51.78 $49,780 - $66,899
-1,292 Reduced 1.59%
80,023 $3.16 Million
Q2 2022

Aug 16, 2022

BUY
$37.35 - $48.3 $19,085 - $24,681
511 Added 0.63%
81,315 $3.58 Million
Q1 2022

May 16, 2022

BUY
$31.97 - $41.06 $27,462 - $35,270
859 Added 1.07%
80,804 $3.22 Million
Q4 2021

Feb 15, 2022

BUY
$31.82 - $40.75 $184,142 - $235,820
5,787 Added 7.8%
79,945 $3.22 Million
Q3 2021

Nov 17, 2021

BUY
$38.47 - $46.42 $27,429 - $33,097
713 Added 0.97%
74,158 $3.02 Million
Q2 2021

Aug 18, 2021

SELL
$38.84 - $51.31 $4,000 - $5,284
-103 Reduced 0.14%
73,445 $3.34 Million
Q1 2021

May 21, 2021

SELL
$39.51 - $51.45 $258,750 - $336,946
-6,549 Reduced 8.18%
73,548 $3.07 Million
Q4 2020

Feb 16, 2021

SELL
$25.81 - $43.62 $27,461 - $46,411
-1,064 Reduced 1.31%
80,097 $3.42 Million
Q3 2020

Nov 17, 2020

SELL
$25.74 - $29.63 $1.04 Million - $1.2 Million
-40,334 Reduced 33.2%
81,161 $2.13 Million
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $1,738 - $2,868
107 Added 0.09%
121,495 $3.26 Million
Q1 2020

May 18, 2020

BUY
$13.9 - $21.83 $701,505 - $1.1 Million
50,468 Added 71.16%
121,388 $2.18 Million
Q4 2019

Feb 18, 2020

BUY
$14.93 - $19.53 $9,853 - $12,889
660 Added 0.94%
70,920 $1.26 Million
Q3 2019

Nov 26, 2019

SELL
$15.2 - $17.69 $3,496 - $4,068
-230 Reduced 0.33%
70,260 $1.09 Million
Q2 2019

Aug 19, 2019

BUY
$14.75 - $17.26 $16,151 - $18,899
1,095 Added 1.58%
70,490 $1.21 Million
Q1 2019

May 15, 2019

BUY
$13.94 - $17.58 $394,920 - $498,041
28,330 Added 68.99%
69,395 $1.12 Million
Q4 2018

Feb 15, 2019

SELL
$13.33 - $18.66 $417,962 - $585,084
-31,355 Reduced 43.3%
41,065 $601,000
Q3 2018

Nov 14, 2018

SELL
$16.68 - $18.41 $3,669 - $4,050
-220 Reduced 0.3%
72,420 $1.32 Million
Q2 2018

Aug 15, 2018

BUY
$16.87 - $20.3 $1.23 Million - $1.47 Million
72,640 New
72,640 $1.23 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Colony Group LLC Portfolio

Follow Colony Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Colony Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Colony Group LLC with notifications on news.